Skip to content
Review

Emerging therapies expected to make a difference in Parkinson's disease management.

Sep 2026 · Parkinsonism & Related Disorders · Vol 152, pp. 108962 · 0 citations · 62 references
Medicine

TL;DR

Four therapeutic approaches that are likely to influence PD management in the coming years are discussed: continuous subcutaneous levodopa infusion, cell-based dopamine replacement, immunotherapies targeting α-synuclein, and gene transfer therapies.

Abstract

Recent advances in Parkinson's disease (PD) therapeutics have generated new opportunities for both symptomatic and disease-modifying treatments. This review discusses four therapeutic approaches that are likely to influence PD management in the coming years: continuous subcutaneous levodopa infusion, cell-based dopamine replacement, immunotherapies targeting α-synuclein, and gene transfer therapies. Subcutaneous levodopa infusion systems have recently demonstrated efficacy in reducing motor fluctuations and represent an important advance toward more physiological dopamine replacement. Stem cell-derived dopaminergic progenitors have revitalized cell replacement research and demonstrated encouraging safety and feasibility in early clinical trials. Although first-generation anti-α-synuclein antibodies have not demonstrated definitive clinical benefit, advances in antibody engineering and biomarker-guided patient selection may help clarify their therapeutic potential. Improvements in viral vector design and delivery are enabling increasingly sophisticated gene-based therapies for both sporadic and genetics forms of PD. Collectively, these advances are expanding therapeutic options and shaping the future management of PD.

View source

Similar papers

Review 2026

Parkinson's disease-Crucial advances and on-going challenges.

This review focuses on some of the groundbreaking advances and the immediate challenges faced by researchers, clinicians, and individuals with PD, as they collaborate to address the great-and ever-growing-clinical need in PD.

Grażyna Söderbom · 0 citations
Review Open access Sep 2026

Dopamine-replacing gene therapy for Parkinson’s disease: biochemical background and current clinical experience

This review summarizes the metabolism, physiological functions, and pathophysiology of dopamine in the striatum and discusses clinical studies investigating gene transfer of dopamine-synthesizing enzymes into the striatum.

H. Ichinose, Yo Sato, Shin-ichi Muramatsu · 0 citations
Review Open access Oct 2026

Precision Medicine and Genotype-Targeted Therapies in Parkinson’s Disease

This article reviews current prospects for disease-modifying therapy in Parkinson’s Disease, with a focus on genotype-targeted treatments for the condition. Over 100 genes and loci are implicated in the pathogenesis of PD. They have varied cellular functions and studies of these roles have yielded insights into the mec...

George Ransley, A. Schapira · 0 citations
Review Nov 2026

[Evolution of strategies for selecting dopaminergic therapy in Parkinson's disease].

Over the past five decades, strategies for dopaminergic therapy in Parkinson's disease (PD) have evolved significantly. Historically treatments aimed to reduce parkinsonism symptoms. Later, the focus shifted to preventing motor fluctuations and dyskinesias, leading clinicians to delay levodopa initiation. As knowledge...

M. R. Nodel · 0 citations
Review Open access Sep 2026

Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies

Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.

Moein Amin, Kaitlyn N. Palmer, A. Samara et al. · 0 citations
Open access Nov 2026

From Mechanistic Insights to Rational Interventions in Parkinson’s Disease: An Integrated Approach with a Patient Perspective

Background/Objectives: Parkinson’s disease (PD) is characterized by the selective loss of nigrostriatal dopaminergic neurons, accompanied by the accumulation and spreading of misfolded α-synuclein aggregates. Proposed mechanisms relevant to PD include gut–brain propagation of pathology via autonomic circuits, autophagy...

Christian Schmidt, Christian Hundeshagen, S. Mihm · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.